VTv Historical Income Statement

VTVT Stock

USD 14.05 0.71 5.32%

Historical analysis of VTv Therapeutics income statement accounts such as Depreciation And Amortization of 77 K, Interest Expense of 11.1 K, Selling General Administrative of 11.5 M or Total Revenue of 9.8 K can show how well vTv Therapeutics performed in making a profits. Evaluating VTv Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of VTv Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining vTv Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether vTv Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in vTv Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy VTv Stock please use our How to Invest in VTv Therapeutics guide.

About VTv Income Statement Analysis

vTv Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to VTv Therapeutics shareholders. The income statement also shows VTv investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

VTv Therapeutics Income Statement Chart

At this time, VTv Therapeutics' Other Operating Expenses is comparatively stable compared to the past year. Research Development is likely to gain to about 18 M in 2025, whereas Selling General Administrative is likely to drop slightly above 11.5 M in 2025.

Selling General Administrative Total Revenue Other Operating Expenses Research Development Total Operating Expenses

Total Revenue

Total revenue comprises all receipts vTv Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of vTv Therapeutics. It is also known as VTv Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from VTv Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into vTv Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in vTv Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy VTv Stock please use our How to Invest in VTv Therapeutics guide.At this time, VTv Therapeutics' Other Operating Expenses is comparatively stable compared to the past year. Research Development is likely to gain to about 18 M in 2025, whereas Selling General Administrative is likely to drop slightly above 11.5 M in 2025.

	2022	2023	2024	2025 (projected)
Interest Expense	15K	13K	11.7K	11.1K
Depreciation And Amortization	92K	90K	81K	77.0K

Interest Expense Depreciation And Amortization

VTv Therapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Minority Interest	Interest Income	Non Operating Income Net Other	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.96	0.15	-0.23	-0.34	0.36	-0.34	-0.36	0.31	-0.33	0.36	0.44	-0.64	-0.14	-0.91	0.54	-0.32	0.85	0.91	0.31	0.09	0.7	-0.3
Interest Expense	0.96		0.11	-0.13	-0.38	0.31	-0.26	-0.29	0.26	-0.26	0.33	0.41	-0.59	-0.07	-0.87	0.67	-0.23	0.77	0.8	0.36	-0.07	0.63	-0.3
Selling General Administrative	0.15	0.11		-0.5	-0.1	-0.02	-0.2	-0.2	-0.14	-0.19	-0.23	-0.19	-0.21	0.29	-0.37	0.25	-0.19	-0.03	0.2	-0.71	0.48	-0.05	0.46
Total Revenue	-0.23	-0.13	-0.5		0.36	-0.26	0.57	0.56	-0.21	0.56	-0.2	-0.06	0.53	0.13	0.49	0.08	0.54	-0.26	-0.38	0.31	-0.59	0.07	-0.25
Gross Profit	-0.34	-0.38	-0.1	0.36		-0.78	0.8	0.81	-0.77	0.81	-0.83	-0.61	0.81	-0.03	0.25	0.17	0.8	-0.54	-0.13	-0.48	0.23	-0.51	0.02
Other Operating Expenses	0.36	0.31	-0.02	-0.26	-0.78		-0.93	-0.93	0.99	-0.93	0.91	0.92	-0.88	-0.02	-0.18	-0.31	-0.91	0.71	0.22	0.51	-0.33	0.75	-0.31
Operating Income	-0.34	-0.26	-0.2	0.57	0.8	-0.93		0.99	-0.91	0.99	-0.85	-0.76	0.93	0.05	0.29	0.33	0.98	-0.65	-0.28	-0.29	0.06	-0.6	0.04
Ebit	-0.36	-0.29	-0.2	0.56	0.81	-0.93	0.99		-0.91	1.0	-0.86	-0.75	0.94	0.14	0.31	0.31	0.99	-0.67	-0.31	-0.31	0.07	-0.62	0.05
Research Development	0.31	0.26	-0.14	-0.21	-0.77	0.99	-0.91	-0.91		-0.91	0.94	0.91	-0.85	-0.06	-0.11	-0.37	-0.89	0.69	0.17	0.58	-0.37	0.73	-0.29
Ebitda	-0.33	-0.26	-0.19	0.56	0.81	-0.93	0.99	1.0	-0.91		-0.86	-0.75	0.93	0.14	0.28	0.34	0.99	-0.65	-0.27	-0.31	0.07	-0.6	0.04
Cost Of Revenue	0.36	0.33	-0.23	-0.2	-0.83	0.91	-0.85	-0.86	0.94	-0.86		0.8	-0.84	-0.2	-0.15	-0.32	-0.86	0.73	0.25	0.69	-0.39	0.73	-0.21
Total Operating Expenses	0.44	0.41	-0.19	-0.06	-0.61	0.92	-0.76	-0.75	0.91	-0.75	0.8		-0.77	-0.02	-0.21	-0.15	-0.73	0.76	0.26	0.66	-0.45	0.78	-0.54
Income Before Tax	-0.64	-0.59	-0.21	0.53	0.81	-0.88	0.93	0.94	-0.85	0.93	-0.84	-0.77		0.15	0.57	0.02	0.91	-0.84	-0.55	-0.38	0.06	-0.74	0.14
Total Other Income Expense Net	-0.14	-0.07	0.29	0.13	-0.03	-0.02	0.05	0.14	-0.06	0.14	-0.2	-0.02	0.15		0.15	0.04	0.18	-0.22	-0.34	-0.24	0.01	-0.17	0.0
Net Income	-0.91	-0.87	-0.37	0.49	0.25	-0.18	0.29	0.31	-0.11	0.28	-0.15	-0.21	0.57	0.15		-0.59	0.25	-0.67	-0.89	-0.01	-0.35	-0.4	0.1
Income Tax Expense	0.54	0.67	0.25	0.08	0.17	-0.31	0.33	0.31	-0.37	0.34	-0.32	-0.15	0.02	0.04	-0.59		0.32	0.22	0.48	-0.03	-0.11	0.11	-0.15
Net Income From Continuing Ops	-0.32	-0.23	-0.19	0.54	0.8	-0.91	0.98	0.99	-0.89	0.99	-0.86	-0.73	0.91	0.18	0.25	0.32		-0.66	-0.29	-0.33	0.11	-0.63	0.02
Minority Interest	0.85	0.77	-0.03	-0.26	-0.54	0.71	-0.65	-0.67	0.69	-0.65	0.73	0.76	-0.84	-0.22	-0.67	0.22	-0.66		0.78	0.58	-0.2	0.86	-0.39
Interest Income	0.91	0.8	0.2	-0.38	-0.13	0.22	-0.28	-0.31	0.17	-0.27	0.25	0.26	-0.55	-0.34	-0.89	0.48	-0.29	0.78		0.12	0.27	0.58	-0.18
Non Operating Income Net Other	0.31	0.36	-0.71	0.31	-0.48	0.51	-0.29	-0.31	0.58	-0.31	0.69	0.66	-0.38	-0.24	-0.01	-0.03	-0.33	0.58	0.12		-0.71	0.55	-0.45
Net Interest Income	0.09	-0.07	0.48	-0.59	0.23	-0.33	0.06	0.07	-0.37	0.07	-0.39	-0.45	0.06	0.01	-0.35	-0.11	0.11	-0.2	0.27	-0.71		-0.35	0.38
Reconciled Depreciation	0.7	0.63	-0.05	0.07	-0.51	0.75	-0.6	-0.62	0.73	-0.6	0.73	0.78	-0.74	-0.17	-0.4	0.11	-0.63	0.86	0.58	0.55	-0.35		-0.38
Extraordinary Items	-0.3	-0.3	0.46	-0.25	0.02	-0.31	0.04	0.05	-0.29	0.04	-0.21	-0.54	0.14	0.0	0.1	-0.15	0.02	-0.39	-0.18	-0.45	0.38	-0.38

Click cells to compare fundamentals

VTv Therapeutics Account Relationship Matchups

VTv Therapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	94K	89K	92K	90K	81K	77.0K
Interest Expense	692K	12K	15K	13K	11.7K	11.1K
Selling General Administrative	7.3M	12.3M	12.2M	11.9M	13.7M	11.5M
Total Revenue	6.4M	4.0M	2.0M	9K	10.4K	9.8K
Gross Profit	(4.6M)	3.9M	1.9M	(13.6M)	(15.6M)	(16.4M)
Other Operating Expenses	18.3M	25.7M	24.6M	25.5M	23.0M	26.4M
Operating Income	(11.9M)	(21.7M)	(22.5M)	(25.5M)	(29.3M)	(30.8M)
Ebit	(12.1M)	(17.6M)	(24.9M)	(25.5M)	(29.3M)	(30.8M)
Research Development	11.0M	13.3M	12.4M	13.5M	12.2M	18.0M
Ebitda	(12.0M)	(17.5M)	(24.8M)	(25.4M)	(29.2M)	(30.7M)
Cost Of Revenue	11.0M	89K	92K	13.6M	12.2M	16.2M
Total Operating Expenses	18.3M	25.7M	24.6M	11.9M	10.7M	10.2M
Income Before Tax	(12.8M)	(17.6M)	(24.9M)	(26.0M)	(29.9M)	(31.4M)
Total Other Income Expense Net	(950K)	4.0M	(2.3M)	(464K)	(533.6K)	(560.3K)
Net Income	(8.8M)	(17.7M)	(25.1M)	(20.3M)	(23.3M)	(24.5M)
Income Tax Expense	100K	(4.0M)	115K	(5.7M)	(6.6M)	(6.9M)
Net Income From Continuing Ops	(12.8M)	(17.7M)	(25.1M)	(27.6M)	(31.8M)	(33.3M)
Net Income Applicable To Common Shares	(17.9M)	(8.5M)	(13.0M)	(19.2M)	(22.0M)	(23.1M)
Minority Interest	(4.3M)	4.7M	(5.9M)	6.1M	5.5M	5.2M
Interest Income	12K	1K	352K	536K	482.4K	262.6K
Net Interest Income	(680K)	(11K)	337K	524K	602.6K	632.7K
Reconciled Depreciation	94K	89K	92K	90K	81K	93.6K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for VTv Stock Analysis

When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

VTv Historical Income Statement

About VTv Income Statement Analysis

VTv Therapeutics Income Statement Chart

Total Revenue

Other Operating Expenses

Total Operating Expenses

VTv Therapeutics income statement Correlations

VTv Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

VTv Therapeutics income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for VTv Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Research Development	+ 0.99	Other Operating Expenses
Ebit	+ 0.99	Operating Income
Ebitda	+ 0.99	Operating Income
Net Income From Continuing Ops	+ 0.99	Ebit
Net Income From Continuing Ops	+ 0.99	Ebitda

Ebitda	- 0.93	Other Operating Expenses
Ebit	- 0.93	Other Operating Expenses
Operating Income	- 0.93	Other Operating Expenses
Ebitda	- 0.91	Research Development
Research Development	- 0.91	Ebit
Research Development	- 0.91	Operating Income